RHINOMED

MAKE EVERY BREATH COUNT

COMMENCEMENT OF RIGHTS TRADING & DESPATCH OF RENOUNCEABLE RIGHTS ISSUE PROSPECTUS

19 May 2020. Melbourne, Australia: Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute[™] and Pronto[™], wishes to confirm that the rights the subject of the Company's Renounceable Rights Issue announced on 11 May 2020 will commence trading under the ASX code RNOR tomorrow, 20 May 2020.

Under the Rights Issue timetable the rights trading will end at the close of trading on Tuesday, 26 May 2020.

The Company also wishes to confirm that the Prospectus including the Entitlement and Acceptance Form in respect of the Renounceable Rights Issue announced to the ASX on 11 May 2020 will be despatched today to Eligible Shareholders in accordance with the rights issue indicative timetable.

This announcement has been authorised for release to the market by the Board.

For more information about Rhinomed's exciting technology, please visit www.rhinomed.global

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 <u>mjohnson@rhinomed.global</u> Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61 (0) 3 9620 3333 rudim@monsoon.com.au